Skip to content

Stellate Ganglion Block and Cerebral Vasospasm

Effect of Early Stellate Ganglion Block for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Trial (BLOCK-CVS)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04691271
Acronym
BLOCK-CVS
Enrollment
202
Registered
2020-12-31
Start date
2021-07-01
Completion date
2024-12-30
Last updated
2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm, Stellate Ganglion Block

Keywords

Cerebral vasospasm, Stellate ganglion block

Brief summary

At present, cerebral vasospasm (cVS) is the main cause of delayed cerebral infarction (DCI), which leads to high disability and mortality rate after aneurysmal subarachnoid hemorrhage. As a consequence, the key of reducing DCI is to prevent cVS. But unfortunately, despite years of efforts, the prevention and treatment of cVS is still a major clinical dilemma and various ways of treatment are still being explored. Recent studies have shown that stellate ganglion block (SGB) can dilate cerebral vessels and alleviate the impact of existing cVS. However, there is no study to evaluate the effect of early application of SGB on the improvement and prevention of cVS after aSAH.

Detailed description

Cerebral vasospasm refers to the extensive segmental or diffuse contraction of cerebral vasculature after aSAH, and cerebral blood flow is significantly reduced, which can lead to delayed cerebral ischemia (DCI) or delayed ischemic neurological dysfunction (DIND). Past studies have shown that if cerebral vasospasm occurs in patients with aSAH, the proportion of ischemic brain injury can be as high as 20%-30%.Obviously, prevention and treatment of CVS are the key to reducing the disability and mortality of aSAH.

Interventions

PROCEDUREStellate ganglion block

After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care.

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age range: 18-65 years old; * Within 48 hours after onset of aSAH,and planning surgical treatment(aneurysm clipping); * Preoperative Hunt-Hess grade 2-3 * Sign informed consent.

Exclusion criteria

* ASA \> grade III; * Patients with posterior circulation aneurysm, ophthalmic aneurysms or internal carotid aneurysms; * patients with multiple aneurysms; * Patients with severe coagulation dysfunction; * Patients with trauma and local infection in the nerve block area; * Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery); * MCA stenosis or infarction was found by preoperative imaging; * Patients with poor temporal window signal revealed by preoperative TCD (clear waveform image could not be obtained); * Allergy to known local anesthetics; * Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of symptomatic vasospasm during hospitalizationan average of 2 weeksSymptomatic vasospasm is defined as new focal or global neurological dysfunction or a decrease in the Glasgow coma score by more than 2 points, and with angiographic vasospasm on TCD or CTA.

Secondary

MeasureTime frameDescription
The incidence of CTA vasospasm on the days 3-5 after operationon the days 3-5 after operationCompared with the preoperative baseline, the corresponding vessel diameter narrowed by more than 30% or new segmental stenosis occurred, not related to atherosclerosis or mechanical artery stenosis caused by arterial clamps or coils.
The incidence of hypoperfusion in CTP diagnosis on the days 3-5 after operationon the days 3-5 after operationThe incidence of hypoperfusion in CTP diagnosis
The incidence of new cerebral infarction observed on the days 90 after operation and discharge .on the days 90 after operation and dischargeNew cerebral infarction is defined only as the appearance of new low-density infarct shadow on CT image compared with preoperation.
The changes of he mean blood flow velocity (mBFV) after operationon the days 3-5 after operationthe changes in the mean blood flow velocity (mBFV) of all large intracranial anterior circulation vessels
Total length of stay in the intensive care unit and hospital.on the 90 daysDays
The incidence of TCD vasospasm during hospitalizationon the days 3-5 after operationThe mean blood flow velocity (MFV) of the middle cerebral artery ≥ 120 cm/s or Lindegaard index (ratio of MFV of the middle cerebral artery to the internal carotid artery) ≥ 3.
All-cause mortality rate up to 90 days.on the 90 daysThe rate
Postoperative delirium incidence during hospitalizationon the days 1-3 after operationThe rate
Postoperative cognitive dysfunctionAt discharge,an average of 2 weeksThe rate
The proportion of remedial treatment after CVSAt discharge,an average of 2 weeksThe rate
Adverse events during hospitalizationAt discharge,an average of 2 weeksMyocardial infarction, cardiac arrest, pulmonary embolism, infection, SGB related complications, etc
The modified Rankin scale at discharge, 30days, and 90 dayson the 30 and 90 daysThe modified Rankin scale ≤2 is defined as good prognosis

Countries

China

Contacts

Primary ContactRuquan Han, M.D., Ph.D
ruquan.han@gmail.com8610-59976660

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026